Intrinsic Analysis of IL-17 and IL-10 Levels in the Serum of Non-Small Carcinoma Lung Cancer Patients at Stage IV compared to other Stages in Kerbala province/Iraq

The study aimed to estimate the levels of cytokines as biomarkers that play an essential role in the progress or suppression of disease for lung cancer as well as to regulate the immunological response of patients with lung cancer. The specimens were taken from the tumoral center/Imam Hussein Hospital/Karbala, and Middle Euphrates Cancer Center/Najaf during the period from (November 2023 to the end of January 2024), where 100 blood samples were collected from patients 65 males and 35 females respectively who suffered from lung cancer and then separated of blood samples to obtain serum and to evaluate the levels of IL-17 and IL-10 by centrifugation to obtain of the serum and it was used to evaluate the levels of IL-17and IL-10 via the using of Enzyme-Linked Immunosorbent Assay (ELISA) as well as it was collected 30 samples as the healthy control group and all collected samples of patients and healthy group with aged around 30 to 78 years, the cases of all patients belong to the type of Non-small carcinoma lung cancer and were divided based on stages as 40(33.3%) of stages I and II, 32 (26.6%) of stage III, and 48(40%) for stage IV. The current study showed the serum levels of IL-17 and IL-10 in stage IV lung cancer patients (0.5268 ± 0.01679) pg/ml were higher significantly (p? 0.05) compared with stage III (0.3503 ± 0.01853)pg/ml and stage I-II (0.2951 ± 0.01142)pg/ml.